Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. (Q51575001)

7 April 2018

title

Acarbose controls postprandial hyperproinsulinemia in non-insulin dependent diabetes mellitus. (English)

1 reference

7 April 2018

1 reference

4

1 reference

7 April 2018

author name string

Inoue I

1

1 reference

7 April 2018

Takahashi K

2

1 reference

7 April 2018

Noji S

3

1 reference

7 April 2018

Negishi K

5

1 reference

7 April 2018

Katayama S

6

1 reference

7 April 2018

publication date

1 June 1997

1 reference

7 April 2018

Diabetes Research and Clinical Practice

published in

1 reference

7 April 2018

volume

36

1 reference

7 April 2018

issue

3

1 reference

7 April 2018

page(s)

143-151

1 reference

7 April 2018

Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Banting lecture 1988. Role of insulin resistance in human disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Circulating proinsulin-like component in man: increased proportion in hypoinsulinemic states.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Serum proinsulin levels at fasting and after oral glucose load in patients with type 2 (non-insulin-dependent) diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

The Bedford survey: ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

The relationships of concentrations of insulin, intact proinsulin and 32-33 split proinsulin with cardiovascular risk factors in type 2 (non-insulin-dependent) diabetic subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

A higher proinsulin response to glucose loading predicts deteriorating fasting plasma glucose and worsening to diabetes in subjects with impaired glucose tolerance.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Effect of troglitazone (CS-045) and bezafibrate on glucose tolerance, liver glycogen synthase activity, and beta-oxidation in fructose-fed rats

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8227%2897%2900045-4

7 January 2021

10.1016/S0168-8227(97)00045-4

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

9237780

1 reference

7 April 2018